The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome by Anita D'Souza, Suzanne.

Slides:



Advertisements
Similar presentations
PLASMA CELL DYSCRASIAS Monoclonal gammopathy of uncertain significance (MGUS)  Idiopathic  Associated with other diseases (autoimmune, infectious, non-heme.
Advertisements

Roman Hájek on behalf of CMG March 27, 2010 Roman Hájek on behalf of CMG March 27, 2010 „Treatment standards, in Czech Republic”.
Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Pomalidomide, Bortezomib.
Thalidomide, Radiation, and Peripheral Stem Cell Transplantation as Combination Treatment for Multiple Myeloma Allison Reczek Department of Biological.
Castle-POES disease successfully treated with Rituximab Nezam Torok, MD PGY2.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Multiple Myeloma Definition:
Multiple Myeloma Definition: B-cell malignancy characterised by abnormal proliferation of plasma cells able to produce a monoclonal immunoglobulin (M protein)
Multiple Myeloma Definition:
Palumbo A et al. Proc ASH 2014;Abstract 175.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Multiple Myeloma March 13, 2012 Suzanne R. Fanning, DO Greenville Health System.
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
Lenalidomide plus dexamethasone is more effective than dexamethasone alone inpatients with relapsed or refractory multiple myeloma regardless of prior.
Prognostication of survival using cardiac troponins and N- terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing.
Morie Gertz Chair Dept. of Medicine
Myeloma hope new treatment in the horizon
Korde N et al. Proc ASH 2012;Abstract 732.
ASCT for AL Seok Jin Kim
Andrzej Jakubowiak  Seminars in Hematology 
San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.
by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S
Treatment of Immunoglobulin Light Chain Amyloidosis
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Clonal competition with alternating dominance in multiple myeloma
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,
by Rafael Fonseca, Richard J. Bailey, Gregory J. Ahmann, S
Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia by N. Frickhofen, E. Müller, M. Sandherr, T. Binder,
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Multiple Myeloma: Diagnosis and Treatment
Current Therapy for Multiple Myeloma
by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen
A young patient with multiple myeloma
Therapy for Relapsed Multiple Myeloma
by Qin Huang Blood Volume 122(1):6-6 July 4, 2013
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.
Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.
Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization  Ivana N.M. Micallef,
Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ What is the optimal therapeutic approach for MM patients with bor-len relapsed/refractory.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun.
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p  Sandy W. Wong, Ute Hegenbart, Giovanni Palladini,
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics  Rajshekhar Chakraborty, Eli Muchtar,
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin.
The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma  Shumaila.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Volume 73, Issue 11, Pages (June 2008)
Therapy for Relapsed Multiple Myeloma
Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict Engraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines.
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation  Shaji Kumar, Waleska S. Pérez, Mei-Jie.
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines  Stephen.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,
by Giovanni Palladini, and Giampaolo Merlini
How I treat Waldenström macroglobulinemia
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.
Treatment options for relapsed and refractory multiple myeloma
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis by Mohammed A. Aljama, M. Hasib Sidiqi,
by Lapo Alinari, and Kristie A. Blum
Autologous Stem Cell Transplantation for POEMS Syndrome
Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective.
Presentation transcript:

The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome by Anita D'Souza, Suzanne R. Hayman, Francis Buadi, Michelle Mauermann, Martha Q. Lacy, Morie A. Gertz, Robert A. Kyle, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J. Russell, Steven Zeldenrust, David Dingli, Thomas E. Witzig, S. Vincent Rajkumar, and Angela Dispenzieri Blood Volume 118(17):4663-4665 October 27, 2011 ©2011 by American Society of Hematology

Plasma VEGF distributions in patients with POEMS syndrome and related disorders. Plasma VEGF distributions in patients with POEMS syndrome and related disorders. IQR indicates interquartile range; AL, immunoglobulin light chain amyloidosis; MM, multiple myeloma; CLS, capillary leak syndrome; PN, peripheral neuropathy; CTD, connective tissue disease/vasculitis; and CD, Castleman disease. Anita D'Souza et al. Blood 2011;118:4663-4665 ©2011 by American Society of Hematology

Serial plasma VEGF levels in patients with POEMS syndrome after treatment. Serial plasma VEGF levels in patients with POEMS syndrome after treatment. The horizontal line represents normal level of VEGF. Most patients had a significant drop in plasma VEGF after treatment and clinical improvement regardless of whether they did (A) or did not (B) achieve a hematologic CR. Clinical course defined for those who either did not drop into the normal range or had vacillating levels. (A) Blue dot represents marked clinical improvement despite continued modest elevation; gold cross, presumed spurious because no intervention after transplantation other than protracted (2-year) prednisone taper for resolving adrenal insufficiency; fuchsia cross, presumed spurious value 1 year after peripheral blood stem cell transplantation (no further interventions made and VEGF improved); and green cross, clinical improvement after transplantation, but plasma VEGF level rose, initially with stable clinical symptoms. Three months after the rise in VEGF, he developed florid POEMS symptoms. Treatments, including lenalidomide, corticosteroids, cyclophosphamide, and finally bevacizumab, yielded no clinical improvement, and he died of his illness 5 months after relapse. Aqua diamond represents clinical improvement but persistent pleural effusion and adrenal insufficiency after peripheral blood stem cell transplantation. (B) Aqua triangle represents initially treated with lendalidomide (1 cycle not tolerated), followed by 8 cycles of bortezomib with initial improvement but then worsening status (and VEGF), so given high-dose cyclophosphamide with resultant reduction in VEGF and continued clinical improvement. Salmon cross represents after high-dose chemotherapy with autologous stem cell transplantation, persistent FDG uptake, high VEGF, so adjuvant radiation given 16 months into diagnosis; blue triangle, after high-dose chemotherapy with autologous stem cell transplantation, he had clinical improvement but developed idiopathic posttransplantation inflammatory arthritis, which persisted for nearly one year; and gold triangle, clinical improvement, but still painful neuropathy and erectile dysfunction 31 months after autologous stem cell transplantation. Because of rising VEGF and slight worsening of positron emission tomography scan, he was started on lenalidomide and dexamethasone. Subsequent VEGF measurement were not yet made. PET indicates; and SUV, standardized uptake value. Anita D'Souza et al. Blood 2011;118:4663-4665 ©2011 by American Society of Hematology